home / stock / gtbp / gtbp news

GTBP News and Press, GT Biopharma Inc. From 03/31/20

Stock Information
Company Name: GT Biopharma Inc.
Stock Symbol: GTBP
Market: OTC
Website: gtbiopharma.com
Menu
GTBP GTBP Quote GTBP Short GTBP News GTBP Articles GTBP Message Board
Get GTBP Alerts

News, Short Squeeze, Breakout and More Instantly...
GTBP - GT Biopharma Announces Commencement of Retreatment of Patient Demonstrating Successful Clinical Benefit following GTB-3550 TriKE(TM) therapy

Patient Achieved Stable Disease BEVERLY HILLS, CA / ACCESSWIRE / March 31, 2020 / GT Biopharma, Inc. (OTCQB:GTBP);(GTBP.PA) a company focused on developing innovative therapeutic treatments based on its proprietary NK cell engager TriKE™ platform announced today that it has been ...
GTBP - UPDATE: GT Biopharma Announces Preliminary Results for GTB-3550 TriKE(TM) Phase I/II Clinical Trial for Treatment of Acute Myeloid Leukemia

Patient Achieves Stable Disease BEVERLY HILLS, CA / ACCESSWIRE / March 19, 2020 / GT Biopharma, Inc. (OTCQB:GTBP) (GTBP.PA) a biotherapeutics company focused on developing innovative therapeutic treatments in oncology and infectious diseases based on its proprietary NK cell engager TriK...

GTBP - GT Biopharma Announces Preliminary Results for GTB-3550 TriKE(TM) Phase I/II Clinical Trial for Treatment of Acute Myeloid Leukemia

BEVERLY HILLS, CA / ACCESSWIRE / March 19, 2020 / GT Biopharma, Inc. (OTCQB:GTBP)(GTBP.PA) a biotherapeutics company focused on developing innovative therapeutic treatments in oncology and infectious diseases based on its proprietary NK cell engager TriKE™ platform announced today tha...

GTBP - GT Biopharma up 20% on plan for coronavirus treatment

Thinly traded nano cap GT Biopharma ( OTCQB:GTBP   +20% ) is, yet another, would-be player in the rush to develop a drug to treat COVID-19. More news on: GT Biopharma, Inc., Healthcare stocks news, Stocks on the move, Read more ...

GTBP - GT Biopharma and Cytovance Biologics Announce Collaboration Agreement TriKE(TM) Therapeutic for Treatment of Coronavirus Infection

BEVERLY HILLS, CA / ACCESSWIRE / March 10, 2020 / GT Biopharma, Inc. (OTCQB:GTBP)(GTBP.PA) a company focused on developing innovative therapeutic treatments based on its proprietary NK cell engager (TriKE™) platform announced today that it had entered into a collaboration agreement wi...

GTBP - GT Biopharma begins testing of GTB-3550

GT Biopharma ( OTCQB:GTBP ) says the first patient has been dosed in a Phase I/II clinical trial of its anti-CD16/IL-15/anti-CD33 TriKE, GTB-3550. More news on: GT Biopharma, Inc., Healthcare stocks news, Read more ...

GTBP - GT Biopharma Announces Dosing First Patient In GTB-3550 TriKE(TM) Phase I/II Clinical Trial

TAMPA, FL / ACCESSWIRE / February 26, 2020 / GT Biopharma, Inc. (OTCQB:GTBP)(GTBP.PA) an immuno-oncology company focused on innovative treatments based on the Company's proprietary NK cell engager (TriKE™) platform announced today that the first patient has been dosed in a Phase I/II ...
GTBP - GT Biopharma Provides Update Concerning Trike(TM) Drug Development Programs and Other Strategic Initiatives

BEVERLY HILLS, CA / ACCESSWIRE / January 21, 2020 / GT Biopharma, Inc. (OTCQB:GTBP) (GTBP.PA) an immuno-oncology company focused on innovative treatments based on the Company's proprietary TriKE™ NK cell engager platform provided the following update concerning its drug development pr...

GTBP - GT Biopharma Announces Solid Tumor Targeting TriKe(TM) Kills

TAMPA, Florida , Oct. 22, 2019 /PRNewswire/ -- GT Biopharma, Inc. (OTCQB: GTBP) (GTBP.PA) an immuno-oncology company focused on innovative treatments based on the Company's proprietary NK cell engager (TriKE™) platform, announced today that Drs. Jeffrey Miller , Martin Felic...

GTBP - GT Biopharma Announces HIV TriKE(TM) Data Demonstrating NK Cell Killing of Patient HIV Infected Cells

TAMPA, Florida , Oct. 3, 2019 /PRNewswire/ -- GT Biopharma, Inc. (OTCQB: GTBP) (GTBP.PA), an immuno-oncology company focused on innovative treatments based on the Company's patent pending TriKE™ technology, announced today that Tim Schacker , M.D., Jeffrey S. Miller , M.D., and t...
Previous 10 Next 10